

November 6, 2025

To Members of the Public,

Oregon Psilocybin Services (OPS) is pleased to share the 2025 amended and adopted rules to implement the Oregon Psilocybin Services Act: [Oregon Administrative Rules \(OAR\) Chapter 333, Division 333: Psilocybin](#). You can also view a PDF version of the amended [2025 OPS Rules with Tracked Changes](#).

OPS considered diverse perspectives throughout the rulemaking process while prioritizing equity, public health and safety, and working within statutory authority under the Oregon Psilocybin Services Act. In this letter, we share a summary of some key points in the final rules adopted this year.

OPS began the formal rulemaking process by inviting members of the public to apply for Rules Advisory Committees (RACs). OPS scheduled separate RACs to discuss different sections of proposed rules, the fiscal impact statement, and the equity impact statement. Holding separate RACs offered additional opportunities for OPS to receive diverse perspectives. OPS received written comments and held public hearings during the September 2025 public comment period. These comments helped to further refine and revise the proposed rules, which have now been adopted as final and will become effective on January 1, 2026.

OPS rules set minimum standards designed to protect public health and safety. The rules are a floor, not a ceiling, and offer flexibility for a variety of operational models. While recommendations made by the RAC members and members of the public during the rulemaking process are important, Oregon Health Authority has authority to adopt rules that may differ from recommendations and public comments.

Some rule changes occurred due to changes in statute including [HB 2387](#) (Oregon Laws 2025, Chapter 147) and [SB 907](#) (Oregon Laws 2025, Chapter 236). The rule changes described below do not include every rule that was amended in

2025. More detailed letters have been sent to licensees, worker permittees and psilocybin training programs, and OPS publishes these communications on our website.

House Bill 2387 was passed by the Oregon Legislature in 2025 and grants specific protections and privileges for people licensed under seven specific boards:

- (A) Oregon Board of Licensed Professional Counselors and Therapists;
- (B) Oregon Board of Naturopathic Medicine;
- (C) Oregon Board of Psychology;
- (D) Oregon Medical Board;
- (E) Oregon State Board of Nursing;
- (F) State Board of Licensed Social Workers;
- (G) State Board of Pharmacy.

Beginning January 1, 2026, facilitators licensed under ORS 475A.325 who are also licensed by one of these seven boards may provide health care or behavioral health services to clients during preparation and integration sessions. For more information, please see the [OPS Dual Licensure and HB2387 Fact Sheet](#).

HB 2387 also amends ORS 475A to require the collection of ‘veteran status’ of clients. The 303 Client Data Form will be updated and will also include new categories in the racial and ethnic identity questions to reflect the REALD and SOGI Demographic Data Collection Standards (OAR 950-030-000), developed through a rulemaking process led by the OHA Equity and Inclusion Division. The updated 303 Client Data Form must be used beginning January 1, 2026. For more information, please refer to [a letter about 2026 Data Requirements](#) sent to Service Centers on September 4, 2025.

OPS amended OAR 333-333-4910 to require quarterly reporting of the number of clients who requested that their data be withheld from data submitted to OHA. This additional requirement will clarify the universe of client data reported by service centers, including clients who opt out of having their data shared with OHA and those who do not opt out.

In addition to changes made to implement legislation OPS made important changes to product label rules in response to public comments and RAC feedback. These changes provide greater clarity to clients and facilitators about potency of psilocybin products. HB 2387 requires psilocin content to be listed on psilocybin product labels, and OAR 333-333-2400 has been adjusted to reflect this requirement. OPS made additional changes to require product labels to display

any other values regarding available, potential or equivalent psilocin or psilocybin that are identified by the laboratory who performed potency testing. Detailed information on compliance with revised label rules has been sent to all licensees and permittees in a separate communication and is also posted on the OPS website.

The changes to label rules compliment amendments to OAR 333-333-5000 that require the [Psilocybin Product Potency Information Document](#) to be discussed with clients during their preparation session. This document supports client decisions on selecting a product type and dose that aligns with their intentions for the administration session. Previously licensees were encouraged to provide this document to clients, but due to ongoing concerns about product potency safety the document is now required to be provided to clients.

Senate Bill 907, passed by the 2025 Oregon Legislature, requires licensed manufacturers and applicants for manufacturer licenses to submit a notarized consent form that shows the owner of the real property approves of its use. Rules have been updated to reflect this requirement, and OPS will publish a revised Property Owner Consent for Manufacturing Psilocybin later this year.

In order to support equitable outcomes for students, OPS adopted a new rule, OAR 333-333-3085, that allows transfer of hours between psilocybin training programs in limited circumstances. If a training program closes or ceases enrolling students after January 1, 2026, other training programs may accept transfer of core training hours from students who previously attended the closed programs.

OPS streamlined requirements for client consent for certain individuals to be present during administration sessions at the request of licensees. OAR 333-333-5000 was amended to remove the requirement that clients provide prior written consent for licensee representatives to be present to assist with operations. OAR 333-333-5020 was also amended to remove the requirements to meet other clients who will participate in a group administration session prior to the session beginning.


Maintaining accurate inventory in the TLC-PTS system is key to preventing product diversion and preserving the integrity of the entire structure for regulated psilocybin products and services. OPS made an important clarification in OAR 333-333-8200 to align with timeframes found in other rule sections. Manufacturers, service centers and laboratories must reconcile all inventory of psilocybin products by 11:59 AM on the next calendar day.

OPS has consistently been committed to preserving client confidentiality and further strengthened confidentiality rules by amending OAR 333-333-4820 to clarify that all client records must be incorporated promptly with other client records and stored at the service center. The additional records described in the amended rule are client records as defined in OAR 333-333-1010(20), and existing rules require these documents to be stored at the service center. The rule amendment merely states that these records must be incorporated with other client records promptly. OPS is unable to address other record keeping requirements for dual licensed facilitators as psilocybin rules operate independently from any requirements imposed by other licensing bodies.

More information about the rulemaking process, including recordings of public hearings, can be found on the [OPS Administrative Rules web page](#). OPS expects to hold public listening sessions each summer and open administrative rules for public comment during the fall of each year. To receive updates about rulemaking in 2026, please sign up for the [OPS distribution list](#).

We would like to thank all the community members who participated in our 2025 public hearings and public listening sessions, and the members of the Rules Advisory Committees for volunteering their time.

Sincerely,

 Samina Panwhar for Andre Ourso  
André Ourso, MPH, JD  
Administrator, Center for Health Protection Public  
Health Division  
Oregon Health Authority



Angie Allbee, MPA  
Section Manager, Oregon Psilocybin Services Public  
Health Division  
Oregon Health Authority